Dabogratinib not checked
Tyra Biosciences, Inc · TYRA-300 · TYRA-300-B01
FollowEvery change as it happens, and a Monday email
Trials
5 active
5 in total · 3 in the EU
What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
- How it’s given
- “Initial dose level of TYRA-300 per protocol, subsequent dose level escalations will occur based on criteria outlined in the protocol.”In the company’s words, NCT06842355 on ClinicalTrials.gov
- Tested for
- FGFR3 Gene Alteration (2 trials), FGFR3 Gene Mutation (2 trials), Low-grade NMIBC, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Fusions, Achondroplasia, Low Grade Upper Tract Urothelial Carcinoma and 12 more
- Main trialPhase 2
- “Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC”In the company’s words, NCT06995677 on ClinicalTrials.gov
- Other names
- TYRA-300 · TYRA-300-B01
Other drugs for Achondroplasia
- NavepegritideAscendis Pharma A/S · Phase 3
- VosoritideBioMarin Pharmaceutical · Phase 3
- LonapegsomatropinAscendis Pharma Endocrinology Division A/S · Phase 3
- KK8398Kyowa Kirin Co., Ltd. · Phase 3
- BMN 333BioMarin Pharmaceutical · Phase 2/3
- ABSK061Abbisko Therapeutics Co, Ltd · Phase 1/2
Coming up4
- NovPhase 1/2 trial completes · ClinicalTrials.gov
- Feb 2028Phase 2 trial completes · ClinicalTrials.gov
- Jan 2030Phase 2 trial completes · ClinicalTrials.gov
- Oct 2030Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Feb 2028 | Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer | |
| Phase 2Recruiting | Jan 2030 | A Study of TYRA-300 in Children With Achondroplasia: BEACH301 | |
| Phase 2Recruiting | Oct 2030 | Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma | |
| Phase 1/2Active, not recruiting | Nov 2026 | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations | |
| Phase 1Active, not recruiting | May 2025 | A Relative Bioavailability and Food Effect Study of TYRA-300-B01 Capsule and Tablet Formulations in Healthy Adult Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026